At a glance
ClinicalIndex Comparison RecordN/ACompleted· 100 enrolled
Drug / intervention
Valiant Evo Thoracic Stent Graft Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Valiant Evo US Clinical Trial
In Brief
A clinical study evaluating Valiant Evo Thoracic Stent Graft System for Aortic Aneurysm, Thoracic. Completed, enrolled 100 participants across 21 sites.
Detailed Summary
The purpose of the Valiant Evo US Clinical Trial is to demonstrate the safety and effectiveness of the Valiant Evo Thoracic Stent Graft System in subjects with a descending thoracic aortic aneurysm (DTAA) who are candidates for endovascular repair.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAortic Aneurysm, Thoracic
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartApr 2016
Primary CompletionDec 2017
Study CompletionMar 2023
TodayJul 2026
First PostedJan 12, 2016
Enrollment StartApr 1, 2016
Primary CompletionDec 1, 2017
Study CompletionMar 2, 2023
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 10.5 years ago
Interventions
Valiant Evo Thoracic Stent Graft Systemdevice
Procedure: thoracic endovascular aneurysm repair (TEVAR)